Abstract
Background: In the last years, Leptospira spp Ballum has increased its representation in human clinical isolations in Cuba. Effective vaccines are needed to control this zoonotic disease. Objective: With the objective of developing a new vaccine candidate able to generate an effective protection against this serovar, two monovalent formulations developed by two highly virulent strains were evaluated (FoBa and FoBb). Methods: Clinical isolates of Leptospira serovar Ballum were subjected to serial passages in hamsters and monovalent vaccines were produced by modified methods developed for vax-SPIRAL?. The vaccine efficacy was tested in both experimental and control hamsters. Results: The Mesocricetus auratus biomodel showed that both formulations generated a protection of 100% against the Ballum lethal infection together to high levels of IgG antibodies and were efficient in the elimination of homologous carrier state but not heterologous carrier states. Conclusion: Both FoBa and FoBb vaccines were protective against leptospirosis with high IgG titers, absence of clinical signs and dead, and absence of leptospires in kidney of sacrificed animals. Keywords: Leptospira, leptospirosis, Mesocricetus auratus, vaccine
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
